Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Net product sales — United States by Quarter
Net product sales — United States ($M) ($M)
Moderna Net product sales — United States: $70M in Q2 2026, down 20.5% from a year earlier.
Latest, Q2 2026
70
Period ended Jun 30, 2026
Change on a year earlier
-20.5%
88 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
17
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 2 (Geographic Disaggregation of Net Product Sales).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net product sales — United States ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 70 | -20.5% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 73 | +135.5% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 264 | +6.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 782 | -35.6% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 88 | -45.7% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 31 | -69.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 249 | -69.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,215 | +33.1% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 162 | +8,000.0% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 100 | +9,900.0% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 804 | -21.6% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 913 | -7.3% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 2 | -99.9% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2023 | Mar 31, 2023 | 1 | -99.9% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,025 | +37.6% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 985 | -17.7% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,450 | -30.7% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 945 | -30.4% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 745 | – | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,197 | – | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 2,093 | – | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,358 | – | Form 10-Q (filed 2022-05-04) ↗ |
Cite this data
StockData. (2026). Moderna Net product sales — United States ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rev-product-sales-us
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.